Mineralys Therapeutics Inc (MLYS)

Nov 20, 2024

Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN

Nov 20, 2024

Nov 20, 2024

Mineralys Therapeutics to Participate in Goldman Sachs Healthcare Conference - MSN

Nov 20, 2024

Nov 18, 2024

Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MSN

Nov 18, 2024

Nov 14, 2024

Mineralys Therapeutics Inc (MLYS) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat

Nov 14, 2024

Nov 14, 2024

HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat

Nov 14, 2024

Nov 13, 2024

(MLYS) Trading Signals - Stock Traders Daily

Nov 13, 2024

Nov 13, 2024

Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia

Nov 13, 2024

Nov 13, 2024

MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews

Nov 13, 2024

Nov 12, 2024

Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance

Nov 12, 2024

Nov 12, 2024

Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 12, 2024

Nov 12, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN

Nov 12, 2024

Nov 11, 2024

Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 11, 2024

Nov 11, 2024

Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks

Nov 11, 2024

Nov 11, 2024

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 11, 2024

Nov 09, 2024

David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat

Nov 09, 2024

Nov 08, 2024

Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com

Nov 08, 2024

Nov 07, 2024

Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo

Nov 07, 2024

Nov 05, 2024

Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat

Nov 05, 2024

Nov 05, 2024

Mineralys Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 05, 2024

Nov 05, 2024

Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan

Nov 05, 2024

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire

Nov 04, 2024

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com

Nov 04, 2024

Nov 04, 2024

Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024

Nov 03, 2024

Objective long/short (MLYS) Report - Stock Traders Daily

Nov 03, 2024

Nov 02, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN

Nov 02, 2024

Oct 31, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024

Oct 30, 2024

Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com

Oct 30, 2024

Oct 30, 2024

Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks

Oct 30, 2024

Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire

Oct 30, 2024

Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times

Oct 30, 2024

Oct 29, 2024

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN

Oct 29, 2024

Oct 25, 2024

Context Therapeutics to Engage Investors at November Conferences - MyChesCo

Oct 25, 2024

Oct 24, 2024

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo

Oct 24, 2024

Oct 23, 2024

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Oct 23, 2024

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times

Oct 22, 2024

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance

Oct 20, 2024

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR

Oct 17, 2024

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com

Oct 16, 2024

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada

Oct 16, 2024

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com

Oct 16, 2024

Oct 15, 2024

Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com

Oct 15, 2024

Oct 15, 2024

Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com

Oct 15, 2024

Oct 15, 2024

Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat

Oct 15, 2024